title: Therapeutic effect of interferon-gamma for prevention of severe infection in X-linked chronic granulomatous disease.
abstract: Chronic granulomatous disease (CGD) is an inherited phagocytic disorder caused by defective oxidative burst activity of neutrophils and monocytes. Patients with CGD may present with recurrent, life-threatening bacterial or fungal infections and often need repeated hospitalization as early as infancy. We report a case of a boy aged 3 years and 1 month with a history of oral thrush, chronic diarrhea, skin abscesses, multiple small joints osteomyelitis, and multiple liver abscesses since 2 months of age. X-linked chronic granulomatous disease was diagnosed by nitroblue tetrazolium test and further confirmed by genetic study using single strand conformation polymorphism (SSCP) analysis and genomic DNA sequencing. Two episodes of aspergillosis with severe aspergillus lung empyema and life-threatening Klebsiella pneumoniae infections were noted in the first 2 years of life despite long-term prophylaxis with trimethoprim-sulfamethoxazole and itraconazole. Recombinant human interferon-gamma (rINF-gamma) 50 microg/m(2) subcutaneous injection 3 times per week was added after his last episode of severe infection. Thereafter, the boy had normal growth and development with no evidence of severe infection during 18 months of follow-up at our outpatient clinic.
authors.affiliation: Department of Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Hui-Ru
authors.initials: HR
authors.lastname: Ma
authors.forename: Shu-Chi
authors.initials: SC
authors.lastname: Mu
authors.forename: Yao-Hsu
authors.initials: YH
authors.lastname: Yang
authors.forename: Chung-Min
authors.initials: CM
authors.lastname: Chen
authors.forename: Bor-Luen
authors.initials: BL
authors.lastname: Chiang
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control*; D002675:Child, Preschool; D006105:Granulomatous Disease, Chronic / Q000150:complications*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007710:Klebsiella Infections / Q000517:prevention & control*; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008172:Lung Diseases, Fungal / Q000517:prevention & control*; D008297:Male; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D011994:Recombinant Proteins; D007371:Interferon-gamma